Skip to main content
Erschienen in: Inflammation Research 9/2009

01.09.2009 | Original Research Paper

The investigation of synovial genomic targets of bucillamine with microarray technique

verfasst von: Kenji Oki, Fumio Tsuji, Koji Ohashi, Masaaki Kageyama, Hiroyuki Aono, Minoru Sasano

Erschienen in: Inflammation Research | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective

To identify the molecular mechanisms of bucillamine activity, global gene expression analysis and pathway analysis were conducted using IL-1β-stimulated human fibroblast-like synovial cells (FLS).

Methods

Normal human FLS were treated with IL-1β in the presence or absence of 10 and 100 μM bucillamine for 6 h. Total RNA was extracted and global gene expression levels were detected using a 44 k human whole genome array. Data were analyzed using Ingenuity pathway analysis.

Results

Numerous pathways were activated by IL-1β stimulation. At both concentrations, bucillamine suppressed nine signal pathways stimulated by IL-1β.

Conclusions

Bucillamine effectively inhibited fibroblast growth factor (FGF) signaling and tight junction signaling activated by IL-1β in FLS. Suppression of these signal pathways may correlate with the pharmacologic mechanisms of bucillamine. In particular, the suppression of FGF signaling by bucillamine is remarkable because the activation of FGF signaling may be involved in rheumatoid arthritis pathology.
Literatur
1.
Zurück zum Zitat Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol. 2004;36:372–8.PubMedCrossRef Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol. 2004;36:372–8.PubMedCrossRef
2.
Zurück zum Zitat Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology. 2006;45:669–75.PubMedCrossRef Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology. 2006;45:669–75.PubMedCrossRef
3.
Zurück zum Zitat Feldmann M, Brennan FM, Foxwell BM, Maini RN. The role of TNFα and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun. 2001;3:188–99.PubMedCrossRef Feldmann M, Brennan FM, Foxwell BM, Maini RN. The role of TNFα and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun. 2001;3:188–99.PubMedCrossRef
4.
Zurück zum Zitat Taberner M, Scott KF, Weininger L, Mackay CR, Rolph MS. Overlapping gene expression profiles in rheumatoid fibroblast-like synoviocytes induced by the proinflammatory cytokines interleukin-1β and tumor necrosis factor. Inflamm Res. 2005;54:10–6.PubMedCrossRef Taberner M, Scott KF, Weininger L, Mackay CR, Rolph MS. Overlapping gene expression profiles in rheumatoid fibroblast-like synoviocytes induced by the proinflammatory cytokines interleukin-1β and tumor necrosis factor. Inflamm Res. 2005;54:10–6.PubMedCrossRef
5.
Zurück zum Zitat Jeong JG, Kim JM, Cho H, Hahn W, Yu SS, Kim S. Effects of IL-1β on gene expression in human rheumatoid synovial fibroblasts. Biochem Biophys Res Commun. 2004;324:3–7.PubMedCrossRef Jeong JG, Kim JM, Cho H, Hahn W, Yu SS, Kim S. Effects of IL-1β on gene expression in human rheumatoid synovial fibroblasts. Biochem Biophys Res Commun. 2004;324:3–7.PubMedCrossRef
6.
Zurück zum Zitat Inoue H, Takamori M, Nagata N, Nishikawa T, Oda H, Yamamoto S, et al. An investigation of cell proliferation and soluble mediators induced by interleukin-1β in human synovial fibroblasts: comparative response in osteoarthritis and rheumatoid arthritis. Inflamm Res. 2001;50:65–72.PubMedCrossRef Inoue H, Takamori M, Nagata N, Nishikawa T, Oda H, Yamamoto S, et al. An investigation of cell proliferation and soluble mediators induced by interleukin-1β in human synovial fibroblasts: comparative response in osteoarthritis and rheumatoid arthritis. Inflamm Res. 2001;50:65–72.PubMedCrossRef
7.
Zurück zum Zitat Eastgate JA, Wood NC, Di Giovine FS, Symons JA, Grinlinton FM, Duff GW. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet. 1988;8613:706–9.CrossRef Eastgate JA, Wood NC, Di Giovine FS, Symons JA, Grinlinton FM, Duff GW. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet. 1988;8613:706–9.CrossRef
8.
Zurück zum Zitat Ministry of Health, Labour, and Welfare (MHLW) Study Group. Manual for the diagnosis and treatment of rheumatoid arthritis (revised edition)—diagnostic manuals and evidence-based guidelines on diagnosis and treatment. Tokyo Japan Rheumatism Foundation. 2004 (in Japanese). Ministry of Health, Labour, and Welfare (MHLW) Study Group. Manual for the diagnosis and treatment of rheumatoid arthritis (revised edition)—diagnostic manuals and evidence-based guidelines on diagnosis and treatment. Tokyo Japan Rheumatism Foundation. 2004 (in Japanese).
9.
Zurück zum Zitat Yokota N, Kuga Y, Kanazawa T, Morishita M, Tanida K, Itou K. Ten years results of bucillamine in the treatment of rheumatoid arthritis. Mod Rheumatol. 2007;17:33–6.PubMedCrossRef Yokota N, Kuga Y, Kanazawa T, Morishita M, Tanida K, Itou K. Ten years results of bucillamine in the treatment of rheumatoid arthritis. Mod Rheumatol. 2007;17:33–6.PubMedCrossRef
10.
Zurück zum Zitat Tsuji F, Aono H, Okamoto M, Sasano M. Bucillamine, a unique anti-rheumatic drug. Curr Top Pharmacol. 2006;10:43–6. Tsuji F, Aono H, Okamoto M, Sasano M. Bucillamine, a unique anti-rheumatic drug. Curr Top Pharmacol. 2006;10:43–6.
11.
Zurück zum Zitat Mazor D, Greenberg L, Shamir D, Meyerstein D, Meyerstein N. Antioxidant properties of bucillamine: possible mode of action. Biochem Biophys Res Commun. 2006;349:1171–5.PubMedCrossRef Mazor D, Greenberg L, Shamir D, Meyerstein D, Meyerstein N. Antioxidant properties of bucillamine: possible mode of action. Biochem Biophys Res Commun. 2006;349:1171–5.PubMedCrossRef
12.
Zurück zum Zitat Hirohata S, Lipsky PE. Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cells. Arthritis Rheum. 1994;37:942–50.PubMedCrossRef Hirohata S, Lipsky PE. Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cells. Arthritis Rheum. 1994;37:942–50.PubMedCrossRef
13.
Zurück zum Zitat Suematsu A, Tajiri Y, Nakashima T, Taka J, Ochi S, Oda H, et al. Scientific basis for the efficacy of combined use of anti-rheumatic drugs against bone destruction in rheumatoid arthritis. Mod Rheumatol. 2007;17:17–23.PubMedCrossRef Suematsu A, Tajiri Y, Nakashima T, Taka J, Ochi S, Oda H, et al. Scientific basis for the efficacy of combined use of anti-rheumatic drugs against bone destruction in rheumatoid arthritis. Mod Rheumatol. 2007;17:17–23.PubMedCrossRef
14.
Zurück zum Zitat Tsuji F, Seki I, Aono H, Odani N, Mizutani K, Okamoto M, et al. Bucillamine mechanism inhibiting IL-1β-induced VEGF production from fibroblast-like synoviocytes. Int Immunopharmacol. 2007;7:1569–76.PubMedCrossRef Tsuji F, Seki I, Aono H, Odani N, Mizutani K, Okamoto M, et al. Bucillamine mechanism inhibiting IL-1β-induced VEGF production from fibroblast-like synoviocytes. Int Immunopharmacol. 2007;7:1569–76.PubMedCrossRef
15.
Zurück zum Zitat Olsen NJ, Sokka T, Seehorn CL, Kraft B, Maas K, Moore J, et al. A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis. 2004;63:1387–92.PubMedCrossRef Olsen NJ, Sokka T, Seehorn CL, Kraft B, Maas K, Moore J, et al. A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis. 2004;63:1387–92.PubMedCrossRef
16.
Zurück zum Zitat Batiwalla FM, Baechler EC, Xiao X, Li W, Balasubramanian S, Khalili H, et al. Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun. 2005;6:388–97.CrossRef Batiwalla FM, Baechler EC, Xiao X, Li W, Balasubramanian S, Khalili H, et al. Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun. 2005;6:388–97.CrossRef
17.
Zurück zum Zitat Devauchelle V, Marion S, Cagnard N, Mistou S, Falgarone G, reban M, et al. DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets. Genes Immun. 2004;5:597–608.PubMedCrossRef Devauchelle V, Marion S, Cagnard N, Mistou S, Falgarone G, reban M, et al. DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets. Genes Immun. 2004;5:597–608.PubMedCrossRef
18.
Zurück zum Zitat Häupl T, Yahyawi M, Lübke C, Ringe J, Rohrlach T, Burmester, et al. Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007;12:328–40.PubMedCrossRef Häupl T, Yahyawi M, Lübke C, Ringe J, Rohrlach T, Burmester, et al. Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007;12:328–40.PubMedCrossRef
19.
Zurück zum Zitat Lindberg J, af Klint E, Ulfgren AK, Stark A, Andersson T, Nilsson P, et al. Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology. Arthritis Res Ther. 2006;8:R47.PubMedCrossRef Lindberg J, af Klint E, Ulfgren AK, Stark A, Andersson T, Nilsson P, et al. Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology. Arthritis Res Ther. 2006;8:R47.PubMedCrossRef
20.
Zurück zum Zitat Malemud CJ. Growth hormone, VEGF and FGF: Involvement in rheumatoid arthritis. Clin Chim Acta. 2007;375:10–9.PubMedCrossRef Malemud CJ. Growth hormone, VEGF and FGF: Involvement in rheumatoid arthritis. Clin Chim Acta. 2007;375:10–9.PubMedCrossRef
21.
Zurück zum Zitat Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev. 1997;18:26–45.PubMedCrossRef Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev. 1997;18:26–45.PubMedCrossRef
22.
Zurück zum Zitat Tsumuki H, Hasunuma T, Kobata T, Kato T, Uchida A, Nishioka K. Basic FGF-induced activation of telomerase in rheumatoid synoviocytes. Rheumatol Int. 2000;19:123–8.PubMedCrossRef Tsumuki H, Hasunuma T, Kobata T, Kato T, Uchida A, Nishioka K. Basic FGF-induced activation of telomerase in rheumatoid synoviocytes. Rheumatol Int. 2000;19:123–8.PubMedCrossRef
23.
Zurück zum Zitat Hurley MM, Lee SK, Raisz LG, Bernecker P, Lorenzo J. Basic fibroblast growth factor induces osteoclast formation in murine bone marrow cultures. Bone. 1998;22:309–16.PubMedCrossRef Hurley MM, Lee SK, Raisz LG, Bernecker P, Lorenzo J. Basic fibroblast growth factor induces osteoclast formation in murine bone marrow cultures. Bone. 1998;22:309–16.PubMedCrossRef
24.
Zurück zum Zitat Kawaguchi H, Chikazu D, Nakamura K, Kumegawa M, Hakeda Y. Direct and Indirect action of fibroblast growth factor 2 on osteoclastic bone resorption in cultures. J Bone Miner Res. 2000;15:466–73.PubMedCrossRef Kawaguchi H, Chikazu D, Nakamura K, Kumegawa M, Hakeda Y. Direct and Indirect action of fibroblast growth factor 2 on osteoclastic bone resorption in cultures. J Bone Miner Res. 2000;15:466–73.PubMedCrossRef
25.
Zurück zum Zitat Manabe N, Oda H, Nakamura K, Kuga Y, Uchida S, Kawaguchi H. Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients. Rheumatology. 1999;38:714–20.PubMedCrossRef Manabe N, Oda H, Nakamura K, Kuga Y, Uchida S, Kawaguchi H. Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients. Rheumatology. 1999;38:714–20.PubMedCrossRef
26.
Zurück zum Zitat Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta. 2008;1784:159–85.PubMed Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta. 2008;1784:159–85.PubMed
27.
28.
Zurück zum Zitat Szekanecz Z, Koch AE. Mechanisms of disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol. 2007;3:635–43.PubMedCrossRef Szekanecz Z, Koch AE. Mechanisms of disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol. 2007;3:635–43.PubMedCrossRef
29.
Zurück zum Zitat Lainer-Carr D, Brahn E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol.. 2007;3:434–42.PubMedCrossRef Lainer-Carr D, Brahn E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol.. 2007;3:434–42.PubMedCrossRef
30.
Zurück zum Zitat Agarwal SK, Brenner MB. Role of adhesion molecules in synovial inflammation. Curr Opin Rheumatol. 2006;18:268–76.PubMedCrossRef Agarwal SK, Brenner MB. Role of adhesion molecules in synovial inflammation. Curr Opin Rheumatol. 2006;18:268–76.PubMedCrossRef
31.
Zurück zum Zitat Wilder RL. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis. 2002;61:ii96–9.PubMed Wilder RL. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis. 2002;61:ii96–9.PubMed
32.
Zurück zum Zitat Anderson JM, Van Itallie CM. Tight junctions and the molecular basis for regulation of paracellular permeability. Am J Physiol. 1995;269:G467–75.PubMed Anderson JM, Van Itallie CM. Tight junctions and the molecular basis for regulation of paracellular permeability. Am J Physiol. 1995;269:G467–75.PubMed
33.
Zurück zum Zitat Engelhardt B, Wolburg H. Transendothelial migration of leukocytes: through the front door or around the side of the house? Eur J Immunol. 2004;34:2955–63.PubMedCrossRef Engelhardt B, Wolburg H. Transendothelial migration of leukocytes: through the front door or around the side of the house? Eur J Immunol. 2004;34:2955–63.PubMedCrossRef
34.
Zurück zum Zitat Palmer G, Busso N, Aurrand-Lions M, Talabot-Ayer D, Chobaz-Péclat V, Zimmerli C, et al. Expression and function of junctional adhesion molecule-C in human and experimental arthritis. Arthritis Res Ther. 2007;9:R65.PubMedCrossRef Palmer G, Busso N, Aurrand-Lions M, Talabot-Ayer D, Chobaz-Péclat V, Zimmerli C, et al. Expression and function of junctional adhesion molecule-C in human and experimental arthritis. Arthritis Res Ther. 2007;9:R65.PubMedCrossRef
35.
Zurück zum Zitat Ebnet K, Suzuki A, Ohno S, Vestweber D. Junctional adhesion molecules (JAMs): more molecules with dual functions? J Cell Sci. 2004;117:19–29.PubMedCrossRef Ebnet K, Suzuki A, Ohno S, Vestweber D. Junctional adhesion molecules (JAMs): more molecules with dual functions? J Cell Sci. 2004;117:19–29.PubMedCrossRef
36.
Zurück zum Zitat Cooke VG, Naik MU, Naik UP. Fibroblast growth factor-2 failed to induce angiogenesis in junctional adhesion molecule-A-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:2005–11.PubMedCrossRef Cooke VG, Naik MU, Naik UP. Fibroblast growth factor-2 failed to induce angiogenesis in junctional adhesion molecule-A-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:2005–11.PubMedCrossRef
37.
Zurück zum Zitat Wallez Y, Huber P. Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim Biophys Acta. 2008;1778:794–809.PubMedCrossRef Wallez Y, Huber P. Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim Biophys Acta. 2008;1778:794–809.PubMedCrossRef
38.
Zurück zum Zitat Jarvis JN, Petty HR, Tang Y, Frank MB, Tessier PA, Dozmorov I, et al. Evidence for chronic, peripheral activation of neutrophils in polyarticular juvenile rheumatoid arthritis. Arthritis Res Ther. 2006;8:R154.PubMedCrossRef Jarvis JN, Petty HR, Tang Y, Frank MB, Tessier PA, Dozmorov I, et al. Evidence for chronic, peripheral activation of neutrophils in polyarticular juvenile rheumatoid arthritis. Arthritis Res Ther. 2006;8:R154.PubMedCrossRef
39.
Zurück zum Zitat Kikuchi H, Isshi K, Hirohata S. Inhibitory effects of bucillamine on the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. Int Immunopharmacol. 2004;4:119–26.PubMedCrossRef Kikuchi H, Isshi K, Hirohata S. Inhibitory effects of bucillamine on the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. Int Immunopharmacol. 2004;4:119–26.PubMedCrossRef
40.
Zurück zum Zitat Munakata Y, Iwata S, Dobers J, Ishii T, Nori M, Tanaka H, et al. Novel in vitro effects of bucillamine: Inhibitory effects on proinflammatory cytokine production and transendothelial migration of T cells. Arthritis Rheum. 2000;43:1616–23.PubMedCrossRef Munakata Y, Iwata S, Dobers J, Ishii T, Nori M, Tanaka H, et al. Novel in vitro effects of bucillamine: Inhibitory effects on proinflammatory cytokine production and transendothelial migration of T cells. Arthritis Rheum. 2000;43:1616–23.PubMedCrossRef
41.
Zurück zum Zitat Steenvoorden MM, Tolboom TC, van der Pluijm G, Löwik C, Visser CP, DeGroot J, et al. Transition of healthy to diseased synovial tissue in rheumatoid arthritis is associated with gain of mesenchymal/fibrotic characteristics. Arthritis Res Ther. 2006;8:R165.PubMedCrossRef Steenvoorden MM, Tolboom TC, van der Pluijm G, Löwik C, Visser CP, DeGroot J, et al. Transition of healthy to diseased synovial tissue in rheumatoid arthritis is associated with gain of mesenchymal/fibrotic characteristics. Arthritis Res Ther. 2006;8:R165.PubMedCrossRef
42.
Zurück zum Zitat Zvaifler NJ. Relevance of the stroma and epithelial–mesenchymal transition (EMT) for the rheumatic diseases. Arthritis Res Ther. 2006;8:210.PubMedCrossRef Zvaifler NJ. Relevance of the stroma and epithelial–mesenchymal transition (EMT) for the rheumatic diseases. Arthritis Res Ther. 2006;8:210.PubMedCrossRef
43.
Zurück zum Zitat Giehl K, Menke A. Moving on: molecular mechanisms in TGFβ-induced epithelial cell migration. Signal Transduct. 2006;6:355–64.CrossRef Giehl K, Menke A. Moving on: molecular mechanisms in TGFβ-induced epithelial cell migration. Signal Transduct. 2006;6:355–64.CrossRef
44.
Zurück zum Zitat González-Mariscal L, Tapia R, Chamorro D. Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta. 2008;1778:729–56.PubMedCrossRef González-Mariscal L, Tapia R, Chamorro D. Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta. 2008;1778:729–56.PubMedCrossRef
45.
Zurück zum Zitat Sawa K, Mochizuki M. Effects of bucillamine on antigen-presenting cells in experimental autoimmune uveitis in rats. Jpn J Ophthalmol. 1997;41:388–95.PubMedCrossRef Sawa K, Mochizuki M. Effects of bucillamine on antigen-presenting cells in experimental autoimmune uveitis in rats. Jpn J Ophthalmol. 1997;41:388–95.PubMedCrossRef
46.
Zurück zum Zitat Yokochi T, Yanagawa A, Nakagawa T, Mizushima Y. Bucillamine, an anti-rheumatic drug, induces a decrease of circulating HLA-DR antigen-positive cells in rheumatoid arthritis patients with remission. Int J Immunother. 1991;7:99–103. Yokochi T, Yanagawa A, Nakagawa T, Mizushima Y. Bucillamine, an anti-rheumatic drug, induces a decrease of circulating HLA-DR antigen-positive cells in rheumatoid arthritis patients with remission. Int J Immunother. 1991;7:99–103.
47.
Zurück zum Zitat Barnetche T, Constantin A, Cantagrel A, Cambon-Thomsen A, Gourraud PA. New classification of HLA-DRB1 alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility. Arthritis Rheum. 2005;52:1063–8.CrossRef Barnetche T, Constantin A, Cantagrel A, Cambon-Thomsen A, Gourraud PA. New classification of HLA-DRB1 alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility. Arthritis Rheum. 2005;52:1063–8.CrossRef
Metadaten
Titel
The investigation of synovial genomic targets of bucillamine with microarray technique
verfasst von
Kenji Oki
Fumio Tsuji
Koji Ohashi
Masaaki Kageyama
Hiroyuki Aono
Minoru Sasano
Publikationsdatum
01.09.2009
Verlag
SP Birkhäuser Verlag Basel
Erschienen in
Inflammation Research / Ausgabe 9/2009
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-009-0021-y

Weitere Artikel der Ausgabe 9/2009

Inflammation Research 9/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.